Format

Send to

Choose Destination
Expert Rev Hematol. 2015 Feb;8(1):57-70. doi: 10.1586/17474086.2015.978281. Epub 2014 Nov 4.

Risk factors for relapse in childhood acute lymphoblastic leukemia: prediction and prevention.

Author information

1
Division of Haematology/Oncology, The Hospital for Sick Children and University of Toronto, Toronto, Ontario, Canada.

Abstract

With current treatment regimens, survival rates for acute lymphoblastic leukemia (ALL) have improved dramatically since the 1980s, with current 5-year overall survival rates estimated at greater than 85%. This success was achieved, in part, through the implementation of risk-stratified therapy. Nevertheless, for a subgroup of patients (15-20%) with newly diagnosed ALL who will ultimately relapse, traditional risk assessment remains inadequate. The risk of relapse may be estimated on the basis of diagnostic features or early treatment response findings. Further progress in this field may thus come from refinement of predictive factors for relapse and treatment adaptation and from the identification of biological subsets of ALL patients who could benefit from specific target therapies. This article summarizes the aspects associated with the identification of predictive factors for relapse in childhood ALL and options available for prevention of disease recurrence.

KEYWORDS:

acute lymphoblastic leukemia; early treatment response; gene expression profiling; minimal residual disease; pediatric; prognostic factor; risk factors for relapse

PMID:
25367188
DOI:
10.1586/17474086.2015.978281
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center